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Abstract
Over the past two decades, Shanghai, the largest megacity in China, has been coping with unprecedented 
growth of its economy and population while overcoming previous underinvestment in the health system 
by the central and local governments. We study the evolution of Shanghai’s healthcare system by analyzing 
“Avoidable Mortality” (AM) – deaths amenable to public health and healthcare interventions, as previously 
defined in the literature. Based on analysis of mortality data, by cause of death, from the Shanghai Municipal 
Center for Disease Control and Prevention, we analyze trends over the period 2000–10 and compare 
Shanghai’s experience to other mega-city regions – New York, London and Paris. Population health status 
attributable to public health and healthcare interventions improved dramatically for Shanghai’s population 
with permanent residency status. The age-adjusted rate of AM, per 1,000 population, dropped from 0.72 
to 0.50. The rate of decrease in age-adjusted AM in Shanghai (30%) was comparable to New York City 
(30%) and Paris (25%), but lower than London (42%). Shanghai’s establishment of the Municipal Center 
for Disease Control and Prevention and its upgrading of public health and health services are likely 
to have contributed to the large decrease in the number and rate of avoidable deaths, which suggests 
that investments in public health infrastructure and increasing access to health services in megacities – 
both in China and worldwide – can produce significant mortality declines. Future analysis in Shanghai 
should investigate inequalities in avoidable deaths and the extent to which these gains have benefitted the 
significant population of urban migrants who do not have permanent residency status.
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Background
Increasing urbanization, worldwide, makes the city a 
strategic unit of analysis for understanding the health sector. 
Shanghai shares many characteristics in common with other 
world cities such as New York, London, Tokyo, Hong Kong 
and Paris (1). These cities are centers of economic growth 
and finance, culture and media, sophisticated transportation 
systems, excellence in medical care, top ranking medical 
schools, institutes of biomedical research, and public health 
infrastructure. They are also characterized by glaring 
inequalities (2), attracting some of the poorest as well as 
the wealthiest populations of their nations. For all these 
reasons, world cities consider themselves unique within their 
respective nations but can be compared to one another to 
explore what lessons might be learned from abroad (3). 
Shanghai, the largest megacity in China, and one of the 
largest in the world (23.46 million inhabitants in 2011), 
experienced remarkable economic growth over the past 
three decades; and since the 1990s, the fastest economic 
growth of any city worldwide (4). As with other megacities in 
emerging industrialized nations, Shanghai has faced massive 
health challenges because the need for such amenities 
as clean drinking water, safe food and basic housing, 
threatened to grow faster than the city’s capacity to develop 
its infrastructure (5). Well before megacities in the Pearl 
River Delta Region, Shanghai confronted unprecedented 
population and economic growth while trying to overcome 
decades of underinvestment in the health system by the 
central and local governments (6).
Shanghai’s healthcare system – like that of other world 
cities – offers some of the most advanced health services 
while at the same time revealing challenges in assuring 
equitable access to healthcare. As one of forty city-regions 
responsible for over two-thirds of the world’s economy and 
most of its innovation (7), it is important to study how such 
megacities are adapting their public health infrastructure 
and healthcare systems to accommodate aging populations 
and the growth of chronic disease. As noted by Shanghai’s 
former Vice Mayor, Shen Xiaoming, the city’s healthcare 
provision has far exceeded national standards (8) and, as 
others have documented, Shanghai is an outlier within 
China (4). Beyond this characteristic of world cities, an 
important question for urban health policy is whether 
the resources invested to upgrade healthcare services and 
the establishment of the Shanghai Municipal Center for 
Disease Control and Prevention have contributed to health 
improvements (9).  
We present here an empirical analysis of Avoidable 
Mortality (AM) – deaths for causes amenable to healthcare 
interventions, in Shanghai, over the period 2000–10. It is 
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designed to capture important dimensions of health system 
performance and represents, so far as we know, the first 
attempt to use this indicator with mortality data from China. 
We present evidence on the decline of AM for Shanghai’s 
registered population, compare Shanghai’s record with 
trends in some of its world city counterparts – London, 
New York City and Paris – and discuss the factors that may 
account for Shanghai’s health improvements. To provide a 
context for this analysis, we begin by reviewing the evolution 
of public health and the healthcare system in Shanghai.
The evolution of Shanghai’s public health and healthcare 
system
The establishment of the Shanghai Municipal Center for 
Disease Control and Prevention in 1998 was the precursor 
to the Chinese Center for Disease Control and Prevention, 
in Beijing, and to similar institutions in 28 province-level 
regions (10). Since then, Shanghai launched major efforts to 
improve its public health and healthcare delivery system. In 
2000, Shanghai implemented a community health reform 
designed to improve access to and continuity of care for older 
people (11). The city also continued to improve its primary 
care and public health systems. Although the central 
government called for a minimum per capita expenditure 
of RMB 25 Yuan for public health initiatives in central and 
western China, Shanghai allocated RMB 70-80 Yuan (12). By 
2001, Shanghai’s government budget for disease prevention 
services was 6.7 times higher than the lowest spending city 
(Chongqing) in China (13).
Following the outbreak of SARS in 2002, Shanghai increased 
investment in public health services, including public 
health surveillance, medical research, and the expansion 
of the healthcare workforce. It also improved its emergency 
medical response capacity and chronic disease management. 
By 2010, Shanghai had become a leader in China’s health 
reform. It established a basic health insurance system for 
employees in 1999 and expanded it to unemployed urban 
residents in 2007 (14). In addition, Shanghai strengthened 
its Center for Disease Control and Prevention, and invested 
significantly in the development of community-based health 
services – immunization, disease prevention services for 
women and infants, and chronic disease management (15). 
These services have been widely available in community 
health centers, medical clinics, and infirmaries. 
Avoidable Mortality (AM) as a measure of health system 
performance
Our health status may depend on behavior and lifestyle, 
the environment in which we live, and our genes more than 
on the healthcare we receive, but for people with illness 
for which treatment exists, access to timely and effective 
healthcare is crucial. Healthcare interventions contribute 
relatively little to broad indicators of health status (16,17). 
Nevertheless, there is solid clinical evidence that some causes 
of premature death are amenable to such interventions. For 
example, maternal death can be prevented with antibiotics, 
safe blood transfusions, and emergency surgical care (18) 
and premature death due to breast cancer can be reduced 
through screening and early detection (19). 
The concept of AM, originally developed by Rutstein and 
colleagues (20), grows out of the notion that an avoidable 
death signals evidence of health system failure. Although 
AM represents only one dimension of health system 
performance, it has been widely adopted in Europe (21) 
and the Organization for Economic Cooperation and 
Development (OECD) has begun publishing rates of AM 
across its member states (22). As a measure of health system 
performance, AM assumes that healthcare, as well as 
health education and screening, have made an appreciable 
contribution to the decline in mortality for selected 
diagnoses (23). Cross-national analysis of recent trends 
indicates that “avoidable deaths” have declined faster than 
other causes of mortality lending some credence to the 
validity of AM as an indicator for public health interventions 
and medical care (24,25). Moreover, analysis across states in 
the U.S. provides evidence that improvements in multiple 
dimensions of health system performance are correlated to 
declines in AM (26).
We rely on the definition of AM (Table 1), as previously used 
in the literature by Nolte and McKee (24). Their list of causes 
of premature death is, in turn, a modification of the work 
of Rutstein et al. (20), Tobias and Jackson (27), Mackenbach 
et al. (28), and Charlton and colleagues (29). AM assumes 
that healthcare can prevent premature death, under 75 years 
of age, from diseases amenable to a combination of different 
interventions, including public health prevention services, 
primary care, as well as selected specialized medical care 
services. In comparisons of national healthcare systems (30), 
as well as cities (31,32), AM is recognized as an important 
dimension of performance. Most recently, Hoffman and 
colleagues (33) have provided further validation for most 
of the causes of death noted by Nolte and McKee (24). 
Since mortality from these causes may also reflect socio-
demographic factors, in comparison to more frequently 
used indicators of population health in China, based on life 
expectancy at birth, infant mortality or  analyses of disease 
burden (34,35), AM captures an important dimension of 
health system performance.
Methods
For Shanghai, data on population and disease-specific deaths 
for the period 1999-2010 are from the Shanghai Municipal 
Center for Disease Control and Prevention. In contrast to New 
York City, Paris and London where mortality data include all 
city residents, the Shanghai data include information only for 
the 14.9 million registered permanent residents. We compare 
Shanghai to New York City, with a population of 8.0 million 
in 2000, to Greater London (7.3 million) and Paris, including 
the 3 départements of its first ring (6.2 million). For New 
York City, data on mortality are from the Bureau of Vital 
Statistics of the New York City Department of Health and 
Mental Hygiene and data on population are from the U.S. 
Bureau of the Census. For Greater London (the 33 boroughs 
to which we refer as London) data on mortality are from the 
Office of National Statistics. For Paris (for which we include 
Paris intra-muros and the 3 départements of the first ring), 
data on mortality are from the Institut National de la Santé et 
de la Recherche Médicale (INSERM) and data on population 
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are from the Institut National de la Statistique et des Etudes 
Economiques (INSEE).
To calculate rates of AM, we rely on Nolte and McKee’s 
definition of causes of death (Table 1). The original Nolte 
and McKee definition includes codes that capture more than 
80% of the deaths included in the definition that McKee used 
more recently in collaboration with Hoffman and colleagues 
(33). We adopt their more restricted definition by counting 
only 50% of the deaths from Ischemic Heart Disease (IHD). 
Although primary prevention contributes significantly to 
reductions in mortality from IHD, it would be inappropriate 
to include all IHD deaths because other factors, including 
genetics, diet and smoking, contribute to these deaths. Our 
approach is consistent with the clinical literature, which 
finds that a considerable proportion of deaths due to IHD 
are amenable to some level of public health and healthcare 
interventions (36). 
The upper age limit adopted by our definition was set at 75 
years since the likelihood that a condition will be amenable 
to intervention, especially in light of the high probability 
of serious comorbidities as well as the reliability of death 
certification, is lower at older age. To age-adjust these data 
for cohorts under 75 years of age, we employed the direct 
method using weights derived from the 2010 United Nations 
(UN) world standard population (37,38). Tables 2 and 3 show 
the number of deaths, the age-specific rates, and the age-
Table 1. Selected avoidable causes of mortality, age group 1–74
Cause of death ICD-9 codes ICD-10 codes
Tuberculosis 010-018,137 A15-19, B90
Septicemia 38 A40-41
Malignancy of colon and rectum 153-154 C18-21
Malignancy of skin 172-173 C44
Malignancy of breast 174-175 C50
Malignancy of cervix and uterus 179,180,182 C53-55
Malignancy of testis 186 C62
Hodgkin’s disease 201 C81
Leukemia 204-208 C91-95
Endocrine diseases, including 
diabetes mellitus
240-279 E0-69
Epilepsy 345 G40-41
Hypertension 401-405 I10-13
Cerebrovascular disease 430-438 I60-69
Influenza 487 J10-11
Pneumonia 480-486 J12-18
Ischemic heart disease* 410-414 I20-25
Peptic ulcer 531-533 K25-27
Appendicitis, abdominal hernia and 
gallbladder disease
540-543; 550-
553; 574.0-
575.1
K35-38; K40-
46; K80-82
Nephritis and nephrosis 580-589 N0-7, 17-19, 25-27
Benign prostatic hyperplasia 600 N40
Maternal death 630-676 O00-99
Source: Nolte and McKee (24)
Table 2. Leading causes of AM in Shanghai, 2000
2000 Number of deaths
Age-specific 
rate/1000
Age-adjusted 
rate/1000
Cerebrovascular disease 7530 0.57 0.36
Ischemic heart disease* 2495 0.19 0.12
Malignancy of colon and 
rectum
1493 0.11 0.08
Endocrine diseases, 
including diabetes mellitus
1299 0.10 0.06
Malignancy of breast 580 0.04 0.03
Nephritis and nephrosis 494 0.04 0.02
Leukemia 488 0.04 0.03
Hypertension 350 0.03 0.02
Tuberculosis 181 0.01 0.01
Malignancy of cervix and 
uterus
166 0.03 0.02
AM= Avoidable Mortality
Source: Shanghai Municipal Center for Disease Control and Prevention; 
calculations by authors.
*All deaths attributed to ischemic heart disease
Table 3. Leading causes of AM in Shanghai, 2010
2010 Number of deaths
Age-specific 
rate/1000
Age-adjusted 
rate/1000
Cerebrovascular disease 4753 0.34 0.20
Ischemic heart disease* 2069 0.15 0.09
Malignancy of colon and 
rectum
1648 0.12 0.07
Endocrine diseases, 
including diabetes mellitus
1410 0.10 0.06
Malignancy of breast 715 0.05 0.03
Leukemia 462 0.03 0.03
Hypertension 400 0.03 0.02
Nephritis and nephrosis 284 0.02 0.01
Malignancy of cervix and 
uterus
239 0.03 0.02
Pneumonia 171 0.01 0.01
AM= Avoidable Mortality
Source: Shanghai Municipal Center for Disease Control and Prevention; 
calculations by authors.
*All deaths attributed to ischemic heart disease
adjusted rates by leading causes of death. 
Results
During the period 2000-10, the age-adjusted rate of AM in 
Shanghai dropped from 0.72 to 0.50 per 1,000 population 
(Figure 1). Cerebrovascular Disease (CVD) was the leading 
cause of AM in Shanghai from 2000 through 2010, but the 
age-adjusted rate of deaths due to CVD decreased from 0.36 
per 1,000 to 0.20 per 1,000 during this time period (Tables 2 
and 3). 
Similarly, the age-adjusted rate of IHD fell from 0.12 to 0.09 
per 1,000 between 2000 and 2010. Tuberculosis fell out of the 
top 10 causes of AM by 2010. The age-adjusted rate of AM is 
lower in Shanghai than in London and New York City and 
higher than in Paris (Figure 1). These city-level differences 
reflect the fact that AM is influenced by a combination of 
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population characteristics, socio-economic status and what 
Schoenbaum and colleagues (25) call “health-care related 
variables” related to health system performance. Within 
these cities, the rate of decrease in age-adjusted AM in 
Shanghai between 2000 and 2010 (30%) was comparable to 
decreases in New York City (30%) and Paris (25%), but less 
than the decrease in London (42%) (Figure 1). By 2010, the 
age-adjusted rate of AM in Shanghai was comparable to 
London.
Limitations of study
Our study has several limitations. First, the accuracy and 
completeness of death records may be subject to coding 
errors. We obtained the primary cause of mortality from 
death certificates, but we were unable to control for other 
causes of death when multiple causes applied. Second, 
although AM is more closely related to the healthcare system 
than conventional measures of population health status, 
e.g. life expectancy at birth, our capacity to identify the 
precise contribution of healthcare is limited. People who die 
prematurely from cancer or IHD may not have benefited 
from disease prevention services, or may have been engaged 
in risky behavior, or once they were diagnosed with IHD or 
cancer, did not receive appropriate medical care. Yet there 
is evidence from Beijing that during the period 1984–99, 
without improvements in healthcare, mortality from IHD 
would have increased much faster than it actually did (39). 
Finally, because data from Shanghai include only deaths 
among registered permanent residents, we do not know how 
inclusion of Shanghai’s large migrant population (9.4 million 
in 2010) would affect Shanghai’s aggregate rate of AM.
Discussion
As policy-makers strive to implement healthcare reforms, 
the experience of Shanghai suggests that public health 
infrastructure investments and improved access to medical 
services in megacities – both in China and worldwide – can 
produce significant mortality declines.
With its rapidly ageing population, urbanization and 
changes in diet and lifestyle, the Chinese healthcare system 
still faces immense challenges. Park and Cai (40) remind us 
that 46% of the employed population work in the informal 
sector and half of these employees are excluded from health 
insurance coverage. Recent evidence suggests that there are 
large socio-economic inequalities in health status within 
Chinese cities (41). Zhao and colleagues (42) provide evidence 
that migrant women in Shanghai face significant access 
barriers to prenatal care. Shanghai’s Municipal Commission 
of Health and Family Planning report that in 2012, the 
Maternal Mortality Rate (MMR) faced by migrants was 9.8 
(per 100,000 births), 2.3 times higher than that of permanent 
residents (4.27). Such evidence, along with the fact that the 
infant mortality rate for the migrant population (6.79 per 
1,000 live births) was 2.5 times higher than for permanent 
residents (2.72) suggests that despite Shanghai’s significant 
health improvements, particularly since 2007, the challenge 
of assuring equitable access to healthcare remains (43). 
Studying rates of AM does not allow us to evaluate specific 
public health interventions, but they are a useful indicator 
for aggregate assessment of a health system’s overall 
performance. Our analysis of changes in these rates, in 
Shanghai, over the past decade suggests that public health 
and healthcare interventions have contributed to a large 
decrease in the number and rate of avoidable deaths. Future 
analysis should investigate neighborhood-level inequalities 
in rates of AM and the extent to which the improvements 
in Shanghai’s health system have reached the 41% of its 
population (9.6 million) who are migrants and have no 
permanent residency status (44). Recent improvements 
suggest that this challenge is recognized¸ but in spite of 
efforts to expand health insurance coverage for migrants, 
there is evidence that most are not eligible for benefits (45,46).
Our finding on the steep decline of AM among Shanghai’s 
registered population suggests that Shanghai has indeed 
made significant health system improvements over the 
2000-10 period. While Shanghai’s substantial investment in 
public health raises critical  questions about regional equity 
within China, the decrease in AM we have found suggests 
that Shanghai’s urban health infrastructure and healthcare 
services, coupled with health reform at the national level  has 
probably contributed to these health improvements. 
Conclusion
Our finding on the steep decline of AM among Shanghai’s 
registered population suggests that Shanghai has indeed 
made significant health system improvements over the 
2000–10 period. 
This accomplishment, as well as the enormous challenges 
associated with changes in lifestyle, population ageing 
and migration, reflect improvements in the broader 
social determinants of health. Yet it is hard to believe 
that Shanghai’s investments in its public health and the 
healthcare system did not also play an important role. 
For example, the substantial decrease in CVD and IHD, 
between 2000 and 2010, probably reflects the healthcare 
system improvements noted earlier, particularly those 
related to the expansion of primary care, emergency care, 
and ICU services. Although there are widespread concerns 
about increases in the rate of Non-Communicable Disease 
(NCD) across China, our findings indicate that age-adjusted 
death rates associated with many types of NCD have either 
decreased or remained stable in Shanghai between 2000 
and 2010. Further investments in public health, changes 
Figure 1. Avoidable mortality in London, New York, Paris and Shanghai, 
ages 0–74, 2000–10
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in lifestyle and environment associated with urbanization 
may prevent additional premature deaths associated with 
NCD. In addition, current policies to rationalize the spatial 
distribution of hospitals, implement a massive IT system and 
begin the process of integrating hospital and primary care, 
may sustain these improvements (8). 
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